FORMULATION ARTICLES
-
![Abstract Modern-GettyImages-490280002]( "Rethinking The \"3:1 Rule\" In LNP Production")
Rethinking The "3:1 Rule" In LNP ProductionA new two-step, ideal-mixing strategy from MIT researchers shows how operating briefly in unstable regions of LNP assembly can unlock precise control of particle size and shape—advancing next-gen RNA manufacturing.
-
![Tumor microenvironment, cancer cells, t-cells, nanoparticles-GettyImages-1449007926]( "Emerging RNA Delivery Strategies For Solid Tumor Oncology")
Emerging RNA Delivery Strategies For Solid Tumor OncologyRNA shows promise in solid tumors, but delivery remains the core challenge. New targeting and delivery strategies aim to overcome tumor barriers and unlock RNA’s full therapeutic potential.
-
![path of exponential growth-GettyImages-2229192052]( "Trends In Oligo Scale-Up & Delivery & How They're Impacting Manufacturing")
Trends In Oligo Scale-Up & Delivery & How They're Impacting ManufacturingHere, a panel of experts at the RNA Leaders Conference give a fantastic overview of where we are today and why, as one expert so nicely put it, “This is one of the most fun times to be an oligo scientist or chemist.”
-
![Researcher at work in DNA genetic laboratory, virus and pathogen detection-GettyImages-1346857647]( "Inside NeoVac's LNP Formulation Strategy: Challenges, Innovation, And What Comes Next")
Inside NeoVac's LNP Formulation Strategy: Challenges, Innovation, And What Comes NextNeoVac CEO Jan Egberts, MD, discusses the science, regulation, and innovation shaping next-gen LNPs—and why true progress in mRNA therapeutics may depend more on understanding than on AI.
-
![Liposome is releasing siRNA, mRNA, or RNA-GettyImages-1656071904]( "Beyond LNPs: 4 Non-Viral Delivery Vehicles Expanding The Possibilities Of mRNA Therapeutics")
Beyond LNPs: 4 Non-Viral Delivery Vehicles Expanding The Possibilities Of mRNA TherapeuticsWhile LNPs have emerged as the most promising non-viral delivery vehicles for mRNA therapeutics thus far, the field is rapidly expanding. To broaden mRNA’s applicability across a wider range of indications, companies are exploring innovative non-viral, non-LNP delivery vehicles, including polymers, engineered virus-like particles, and more.
-
![Healthcare collaboration-GettyImages-1724755569]( "Translating An Early-Stage mRNA Therapeutic Into The Clinic")
Translating An Early-Stage mRNA Therapeutic Into The ClinicIn the following Q&A, Ethris CMO Thomas Langenickel shares some of his biggest questions and observations about the evolving mRNA therapeutics space that are the most impactful in translating early-stage RNA candidates into the clinic — particularly when that drug product boasts a novel formulation.
FORMULATION VIDEOS
Explore a structured approach to optimizing and scaling plasmid DNA production using E. coli, with insights into key growth parameters, benchtop feasibility, and pilot-scale performance.
Explore how lipid nanoparticles are revolutionizing non-viral gene editing with scalable, efficient delivery for both ex vivo and in vivo applications, which features new CRISPR-LNP data in T cells.
In this segment, Replicate Biosciences’ Andy Geall, Qian Ruan, & Alex Aust identify the most promising technological and raw material innovations that are influencing the drug substance and drug product production processes at CDMOs.
Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery, Strand Therapeutics, share their expectations on which scientific advancements/characteristics will be most important for LNP-delivery of mRNA/RNA cargo in the future.
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
![INFORS Scientist, male]( "Ready To Amplify Plasmid (pDNA) In Bacteria?")
Explore how to use and amplify pDNA from the development of recombinant proteins and viral vectors to advanced bio-therapeutics such as mRNA vaccines.
-
![GettyImages-1269045566-rna]( "Standardize Scale-Up And Reduce Time To Market With Mixing Cartridges")
Despite the momentum of the RNA-LNP therapeutic market, significant manufacturing challenges remain. However, the right mixing could solve three of these key challenges regarding instrumentation.
-
![mRNA GettyImages-1356994684]( "Freezing mRNA: Best Practice")
By following some of the best practices in freezing mRNA, you can effectively balance product quality, cost-effectiveness, process safety, and efficiency.
-
![GettyImages-1275317360-lab-cell-gene-research-scientist-development-discovery]( "Scale-Up And Manufacturing Of Self-Amplifying RNA-LNPs")
This poster shows the work to scale up COVID-19 self-amplifying RNA-Lipid nanoparticle using PNI developed ionizable lipid and formulation from 0.2, to 50 mg scale using PNI’s Manufacturing Platform.
-
![GettyImages-2174865889 lab, research]( "Tangential Flow Filtration Of LNPs Results In 10X Concentration Within 20 Minutes")
Dive into a study that details how a single-pass tangential flow filtration system can achieve a tenfold concentration of liposomal nanoparticles in under 20 minutes.
-
![GettyImages-508496956-dna]( "mRNA: Challenges And Strategies Related To The DNA Template Process")
Encapsulated mRNA–LNP creation begins with synthesizing the DNA template. Explore insights on DNA template synthesis, the challenges and strategies of generating a DNA template using PCR, and more.
-
![GettyImages-970394878-genetic-engineering-gene-editing-dna]( "Genome Editing Using mRNA-Lipid Nanoparticles For CAR T Cell Therapy")
Gene delivery platforms must support a diversity of genetic engineering strategies for genomic medicine development. Learn how lipid nanoparticles can accelerate development from discovery to scale-up.
